首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1736857

2026-2032 年牛血漿衍生物市場（依衍生物類型、應用及地區分類）

Bovine Blood Plasma Derivatives Market By Derivatives Type (Immunoglobulin, Fibrinogen), Application (Pharmaceutical Industry, Diagnostics Industry), & Region for 2026-2032

出版日期: 2025年05月07日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026-2032年牛血漿衍生物市場評估

血漿衍生物在疫苗和治療產品中的使用日益增多，推動了牛血漿衍生物的採用。富含蛋白質的營養補充品越來越受歡迎，尤其是在體育和健康產業，推動市場規模在 2024 年超過 19.6 億美元，到 2032 年達到約 30.6 億美元的估值。

此外，人們對動物健康和營養的認知不斷提高，也推動了獸藥對血漿衍生物的需求，從而促進了牛血漿衍生物的採用。發展中地區的經濟成長和肉類消費量的增加，使得該市場在2026年至2032年間的複合年成長率達到5.70%。

牛血漿衍生物市場定義/概述

牛血漿衍生物是從牛血漿（血液去除細胞後剩餘的液體部分）中提取的成分。這些衍生物含有多種蛋白質，包括免疫球蛋白、白蛋白和纖維蛋白原，並經過加工以確保安全性和有效性。由於其豐富的營養和生物學特性，它們在獸醫和人類醫學中都發揮著重要作用。

牛血漿衍生物在各領域有廣泛的應用。在醫療領域，由於其高蛋白質含量和生物活性，它們被用於治療免疫力缺乏、創傷治療和外科手術。在食品工業中，它們可用作膳食補充劑和蛋白粉、運動營養配方等產品中的功能性成分。此外，在農業領域，血漿衍生物可用於牲畜飼料，以促進牲畜生長和增強免疫力。

動物用藥品產業日益成長的需求將如何促進牛血漿衍生物的採用？

免疫力缺乏缺陷症和出血性疾病的日益流行，催生了對血漿療法的巨大需求，成為牛血漿衍生物市場的主要驅動力。世界衛生組織 (WHO) 預計，2021 年至 2023 年間，全球原發性免疫力缺乏的盛行率將增加 28%，這必然要求增加血漿衍生物的產量。在關鍵進展方面，賽默飛世爾科技於 2024 年 1 月宣布擴建其在北美的牛血漿採集設施，而默克則透過引進新的血漿分餾技術，提高了生產效率和產品品質。

牛血漿衍生物在細胞培養基和生物技術研究中的應用日益廣泛，是另一個關鍵的市場驅動力。根據美國國立衛生研究院的報告，到2023年，使用牛血漿成分進行細胞培養研究的支出將增加35%，達到8.92億美元。這一趨勢促使業界採取了重大舉措，例如SAFC Biosciences於2024年3月推出了一款牛血漿的先進細胞培養補充劑，GE Healthcare Life Sciences則擴大了其用於生物製藥生產的牛生長因子產品組合。

動物用藥品產業需求的成長是第三個關鍵促進因素，這得益於動物保健和營養領域應用的不斷成長。美國農業部記錄到，2023年，動物用藥品中牛血漿衍生物的使用量與前一年同期比較去年同期成長了42%。近期的發展包括：碩騰公司於2024年2月推出了一系列基於血漿的牲畜營養補充劑；勃林格殷格翰動物保健公司與一家領先的血漿採集公司建立了戰略合作夥伴關係，從而加強了獸藥生產的供應鏈。

疾病傳播風險會限制牛血漿市場的成長嗎？

牛血漿衍生物市場面臨監管挑戰，阻礙了其成長。圍繞動物性產品的收集、加工和使用的嚴格監管通常需要大量的測試和合規措施。這會導致製造商成本增加，小型企業的市場准入受限，並可能影響整體市場擴張。

另一個主要限制因素是疾病傳播的風險。對牛腦病變（BSE）等通用感染疾病的擔憂，可能導致消費者對使用牛產品猶豫不決。這種風險需要嚴格的安全通訊協定，並可能使潛在買家望而卻步，尤其是在食品安全意識日益增強的地區。

畜牧業的市場波動也會影響牛血漿衍生物的供應。由於疾病爆發、農業實踐變化或市場需求等因素導致牛數量波動，可能導致原料供應不穩定。這種不穩定會擾亂生產計畫，並導致價格波動，從而影響該行業企業的盈利。

Increased use of plasma derivatives in vaccines and therapeutic products is propelling the adoption of bovine blood plasma derivatives. The rising popularity of protein-rich nutritional supplements, particularly in sports and health industries is driving the market size to surpass USD 1.96 Billion valued in 2024 to reach a valuation of around USD 3.06 Billion by 2032.

In addition to this, increasing awareness of animal health and nutrition supports the demand for plasma derivatives in veterinary medicine is spurring up the adoption of bovine blood plasma derivatives. Growing economies and increasing meat consumption in developing regions is enabling the market to grow at a CAGR of 5.70% from 2026 to 2032.

Bovine Blood Plasma Derivatives Market: Definition/ Overview

Bovine blood plasma derivatives are components extracted from the blood plasma of cattle, which is the liquid part of blood that remains after cells have been removed. These derivatives include a variety of proteins, such as immunoglobulins, albumin, and fibrinogen, and are often processed to ensure safety and efficacy. They play a significant role in both veterinary and human medicine, owing to their rich nutritional and biological properties.

Bovine blood plasma derivatives have diverse applications across several fields. In the medical sector, they are used in the formulation of therapies for immune deficiencies, wound healing, and surgical applications, thanks to their high protein content and biological activity. In the food industry, they serve as nutritional supplements and functional ingredients in products like protein powders and sports nutrition formulations. Additionally, in agriculture, plasma derivatives are used in animal feed to enhance growth and immunity in livestock.

How will Rising Demand from the Veterinary Pharmaceutical Industry Increase Adoption of Bovine Blood Plasma Derivatives?

The increasing prevalence of immunodeficiency disorders and bleeding conditions has emerged as a primary driver for the bovine blood plasma derivatives market, creating substantial demand for plasma-based therapeutics. According to the World Health Organization, the global prevalence of primary immunodeficiency disorders increased by 28% between 2021 and 2023, necessitating increased production of plasma derivatives. In a significant development, Thermo Fisher Scientific announced in January 2024 its expansion of bovine plasma collection facilities across North America, while Merck's introduction of new plasma fractionation technologies has enhanced production efficiency and product quality.

The growing application of bovine plasma derivatives in cell culture media and biotechnology research represents another crucial market driver. The National Institutes of Health reported that research funding for cell culture studies utilizing bovine plasma components increased by 35% in 2023, reaching USD 892 Million. This trend has prompted major industry movements, with SAFC Biosciences launching an advanced cell culture supplement derived from bovine plasma in March 2024, while GE Healthcare Life Sciences expanded its portfolio of bovine-derived growth factors for biopharmaceutical production.

Rising demand from the veterinary pharmaceutical industry stands as the third significant driver, with increasing applications in animal healthcare and nutrition. The U.S. Department of Agriculture documented a 42% increase in the usage of bovine plasma derivatives in veterinary medicines during 2023 compared to the previous year. Recent developments include Zoetis's February 2024 announcement of a new line of plasma-based nutritional supplements for livestock, while Boehringer Ingelheim Animal Health's strategic partnership with a leading plasma collection company has strengthened its supply chain for veterinary therapeutics production.

Will Risk of Disease Transmission Restrain Bovine Blood Plasma Market Growth?

The bovine blood plasma derivatives market faces regulatory challenges that can hinder its growth. Strict regulations surrounding the collection, processing, and use of animal-derived products often require extensive testing and compliance measures. This can lead to increased costs for manufacturers and may limit market entry for smaller companies, impacting overall market expansion.

Another significant restraint is the risk of disease transmission. Concerns about zoonotic diseases, such as Bovine Spongiform Encephalopathy (BSE), can lead to consumer hesitance regarding the use of bovine-derived products. This risk necessitates rigorous safety protocols and can deter potential buyers, particularly in regions with heightened awareness of food safety issues.

Market fluctuations in the cattle industry can also affect the supply of bovine blood plasma derivatives. Variations in cattle populations due to factors like disease outbreaks, changing agricultural practices, or market demands can create instability in the availability of raw materials. This inconsistency can hinder production planning and lead to price volatility, impacting profitability for companies in the sector.

Category-Wise Acumens

Will Thrombin Segment Dominate in Bovine Blood Plasma Derivatives Market?

The thrombin segment maintains its dominant position in the bovine blood plasma derivatives market, driven by its crucial role in surgical procedures, wound healing, and diagnostic applications. According to the U.S. Food and Drug Administration, thrombin-based products accounted for 45% of all bovine plasma derivative approvals in 2023, highlighting its significant market share. This dominance has spurred major developments, with Pfizer announcing in February 2024 the expansion of its thrombin production facilities in Michigan, while Baxter International launched an advanced thrombin-based surgical sealant featuring enhanced stability and efficacy.

The increasing adoption of thrombin-based hemostatic agents in minimally invasive surgeries has further strengthened its market position. The European Medicines Agency reported a 38% increase in thrombin product usage across surgical procedures between 2022 and 2023. Recent developments include Johnson & Johnson's March 2024 introduction of a novel thrombin delivery system for laparoscopic surgeries, while Takeda Pharmaceutical's acquisition of a specialized plasma derivatives manufacturer has bolstered its thrombin product portfolio.

Which Factors Enhance the Use of Bovine Blood Plasma Derivatives in the Pharmaceutical Industry?

The pharmaceutical industry maintains its leadership in the bovine blood plasma derivatives market, driven by increasing applications in drug development, vaccine production, and therapeutic formulations. According to the U.S. Food and Drug Administration, pharmaceutical applications accounted for 62% of all approved bovine plasma derivative products in 2023, representing a significant market share. This dominance has prompted major developments, with GlaxoSmithKline announcing in January 2024 a $300 million investment in plasma processing facilities, while Novartis expanded its bovine-derived pharmaceutical portfolio through advanced fractionation technologies.

The industry's growth is further fueled by the rising demand for plasma-based vaccines and immunological products. The World Health Organization reported that pharmaceutical companies increased their bovine plasma derivative usage by 43% in 2023 for vaccine development and production. Recent developments include Merck's March 2024 launch of a new plasma-derived growth factor supplement for cell culture applications, while Pfizer's strategic partnership with a leading plasma collection network has strengthened its supply chain for pharmaceutical product development.

Country/Region-wise Acumens

Will Diversity And Vast Workforce in North America Drive Bovine Blood Plasma Derivatives Market Growth?

North America is known to embrace technological advancements leading to early adoption and widespread use of bovine blood plasma derivatives. This is likely to attract a mature ecosystem of established vendors, diverse solutions, and skilled professionals. The higher disposable income and knowledge regarding technological benefits in comparison to other regions is bolstering the application and willingness to invest in Bovine Blood Plasma Derivatives in the organizations located in North America.

Also, the diversity and vast workforce in North America in the prevalent and emerging organizations in industrialized countries like the U.S., Canada are necessitating advanced timekeeping solutions catering to various industries, employee types, and complex work arrangements.

Furthermore, the implementation of strict wage and hour laws along with a strong focus on workplace regulation is driving the demand for accurate and compliant timekeeping solutions to avoid penalties and legal issues. Introduction of well-developed internet infrastructure in tech-savvy environment create a fertile ground for cloud-based solutions and advanced features like biometrics and AI-powered analytics. These innovations are enabling North America dominate the Bovine Blood Plasma Derivatives market during the forecast period.

Will Increasing Research Activities Enhance Adoption of Bovine Blood Plasma Derivatives in Asia Pacific?

The bovine blood plasma derivatives market in Asia Pacific is experiencing remarkable growth, driven by expanding healthcare infrastructure, increasing research activities, and rising demand for plasma-based products across pharmaceutical and biotechnology sectors. According to China's National Medical Products Administration, the regional market for bovine plasma derivatives grew by 38% in 2023, reaching a value of USD 1.5 Billion. This growth trajectory has attracted significant investments, with Samsung Biologics announcing in February 2024 the establishment of a state-of-the-art plasma processing facility in South Korea, while Japan's Takeda Pharmaceutical expanded its presence through a strategic partnership with leading Chinese biotechnology firms.

The region's rapid advancement in biotechnology research and development is fueling market expansion. The Indian Council of Medical Research reported a 45% increase in research projects utilizing bovine plasma derivatives during 2023, with total funding reaching ₹850 crore (USD 103 Million). Recent developments include Thai-based Charoen Pokphand Group's March 2024 launch of Asia's largest bovine plasma collection network, while Singapore's Bio*One Capital invested USD 200 Million in developing advanced plasma fractionation technologies.

Competitive Landscape

The bovine blood plasma derivatives market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the bovine blood plasma derivatives market include:

CSL Limited
Grifols S.A.
Kedrion S.p.A.
Baxter International, Inc.
Shire (now part of Takeda)
Octapharma AG
Biotest AG
Fresenius Kabi AG
LFB Group
Sangamo Therapeutics, Inc.
HemaCare Corporation
Hemex Health
HemaSource, Inc.
Proliant Biologicals
Thermo Fisher Scientific, Inc.
American Blood Resources Association (ABRA)
Bovine Blood Products Co.
Centeon (a part of the LFB Group)
PPL Therapeutics
PlasmaLyte

Latest Developments

In November 2023, Baxalta announced the expansion of its bovine blood plasma derivatives production facility to increase capacity and meet rising global demand for immunoglobulin therapies.
In September 2023, Grifols launched a new line of bovine-derived albumin products aimed at enhancing patient outcomes in critical care settings, highlighting advancements in product purity and efficacy.

1 INTRODUCTION OF GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET, BY DERIVATIVES TYPE

5.1 Overview
5.2 Immunoglobulin
5.3 Fibrinogen
5.4 Serum Albumin
5.5 Fetal Bovine Serum
5.6 Thrombin
5.7 New Born Calf Serum

6 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION

6.1 Overview
6.2 Pharmaceutical Industry
6.3 Diagnostics Industry
6.4 Cell Culture/ Biotechnology
6.5 Research and Development
6.6 Food Industry
6.7 Cosmetic Industry

7 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East & Africa

8 GLOBAL BOVINE BLOOD PLASMA DERIVATIVES MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 CSL Limited
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Grifols S.A.
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Kedrion S.p.A.
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Baxter International, Inc.
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Shire (now part of Takeda)
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Octapharma AG
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Biotest AG
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Fresenius Kabi AG
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 LFB Group
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 Sangamo Therapeutics, Inc.
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments